ECHDC2

ECHDC2 is a mitochondrial enzyme that modulates branched-chain amino acid levels and fatty acid metabolism, with functional consequences for ischemia/reperfusion injury susceptibility and cancer cell survival (PMID:24108764, PMID:31437751). ECHDC2 overexpression in cardiomyocytes increases intracellular leucine and valine and sensitizes cells to ischemia/reperfusion injury, while its knockdown confers resistance (PMID:24108764). In gastric cancer cells, ECHDC2 recruits the E3 ubiquitin ligase NEDD4 to promote ubiquitination and proteasomal degradation of MCCC2, thereby suppressing P38 MAPK signaling, aerobic glycolysis, and proliferation (PMID:38783226).

1. 2013 Medium

   Establishing ECHDC2 as a mitochondrial protein in cardiomyocytes whose expression level determines susceptibility to ischemia/reperfusion injury — and linking it to branched-chain amino acid handling rather than canonical oxidative phosphorylation — defined its first functional context.

   Evidence Overexpression and knockdown in cardiomyocytes with I/R injury assay and GC-MS metabolite profiling; subcellular fractionation confirming mitochondrial localization

   PMID:24108764

   Open questions at the time

   • Enzymatic activity and substrate specificity of ECHDC2 remain undefined
   • Mechanism by which elevated leucine/valine increases I/R injury susceptibility is unexplained
   • No structural or kinetic characterization of the protein
2. 2019 Medium

   A genome-wide CRISPR screen identified ECHDC2 as required for cancer cell survival in suspension (anoikis escape), extending its role from cardiac metabolism to fatty acid metabolism–dependent tumor cell fitness.

   Evidence GeCKO CRISPR/Cas9 knockout screen in high-grade serous ovarian cancer cells validated by siRNA knockdown and suspension growth assay

   PMID:31437751

   Open questions at the time

   • The specific lipid metabolic pathway through which ECHDC2 supports suspension survival is not delineated
   • Whether ECHDC2 enzymatic activity or a scaffolding function is required was not tested
3. 2024 Medium

   Demonstrating that ECHDC2 physically interacts with the E3 ligase NEDD4 to drive ubiquitination and degradation of MCCC2 provided the first defined molecular mechanism, linking ECHDC2 to suppression of P38 MAPK signaling and aerobic glycolysis in gastric cancer.

   Evidence Reciprocal co-immunoprecipitation, immunofluorescence colocalization, ubiquitination assays, and in vivo xenograft models in gastric cancer cells

   PMID:38783226

   Open questions at the time

   • Whether ECHDC2 acts catalytically on MCCC2 or solely as an adaptor/scaffold for NEDD4 is unresolved
   • Relevance of the ECHDC2–NEDD4–MCCC2 axis to cardiac I/R injury has not been tested
   • The relationship between this ubiquitination mechanism and ECHDC2's metabolic enzyme function is unclear

• The intrinsic enzymatic activity of ECHDC2, its endogenous substrates, and how its metabolic and signaling (NEDD4/MCCC2) functions are integrated across tissue contexts remain unresolved.
• No enzymatic assay or substrate identification has been reported
• No structural data exist for ECHDC2
• Whether the branched-chain amino acid phenotype and the MCCC2 degradation phenotype are mechanistically connected is unknown